800-872-2273

Clinical Trials and Studies

Your participation matters. Help us discover and cure!

Contact us at (800) USC-CARE (800-872-2273)

Study Title Principal Investigator
Join a USC Study on Vaping and E-Cigarette Use
<p>The number of people who vape&nbsp;and use e-cigarettes has been increasing, particularly&nbsp;among young adults. We want to examine how factors associated with vaping and e-cigarette use, such as flavoring and nicotine level, effect people's thoughts, feelings, and behaviors. If you participate in this study, we will ask you to complete the study remotely, complete some questionnaires about your nicotine and tobacco use history, and vape e-liquids that we provide to you.</p><p><br></p>
Recruiting | vaping | Not Multisite
Adam Matthew Leventhal, PhD
Predicting Ipsilesional Motor Deficits in Stroke with Dynamic Dominance Model
Some stroke patients have severe weakness in one arm and&nbsp;must rely on their less-affected arm for daily activities. Previous research has shown that in some patients, the less-affected arm also experiences weakness due to the stroke. This research is being done to find out if the less-affected arm can be trained to perform faster and better during daily activities. Approximately 180 people will take part in this research study at Hershey Medical Center and University of Southern California.
Recruiting | stroke | Not Multisite
Carolee Winstein, BA, BS, MS, PhD
Pivotal Study to Evaluate the Safety and Effectiveness of the CereVasc® eShunt® System in the Treatment of Normal Pressure Hydrocephalus
The STRIDE study is a prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.
Recruiting | Brain Diseases | Not Multisite
Kasra Khatibi, MD
A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma
This is an open label, multi-center, single arm phase II study. The study will investigate the efficacy of sodium cridanimod in conjunction with progestin therapy in a population of patients with recurrent or persistent PrR-negative endometrial cancer. Eligible patients will be enrolled into the study and administered sodium cridanimod in combination progestin therapy. Objective responses will be assessed at 12 week intervals. Patients will be treated for a 12 month period, followed by an additional 12 month follow up period or to disease progression whichever occurs first. Important objectives of the study are to investigate the effect of sodium cridanimod in conjunction with progestin therapy on the level of PrR in tumor tissue and how this correlates to efficacy. To accomplish this objective, some of the patients enrolled in the study will undergo two tumor biopsies that will allow measurement of PrR levels in the tumor tissue before the treatment and after 4 weeks of therapy.
Recruiting | Gynecologic Cancers | Multisite
Lynda Roman
View Research Profile
Powered by SC CTSI